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Recent studies have signiﬁcantly improved our understanding of the role microRNAs
(miRNAs) play in regulating normal hematopoiesis. miRNAs are critical for maintaining
hematopoietic stem cell function and the development of mature progeny.Thus, perhaps it
is not surprising that miRNAs serve as oncogenes and tumor suppressors in hematologic
malignancies arising from hematopoietic stem and progenitor cells, such as the myeloid
disorders. A number of studies have extensively documented thewidespread dysregulation
of miRNA expression in human acute myeloid leukemia (AML), inspiring numerous
explorations of the functional role of miRNAs in myeloid leukemogenesis. While these
investigations have conﬁrmed that a large number of miRNAs exhibit altered expression in
AML, only a small fraction has been conﬁrmed as functionalmediators ofAMLdevelopment
or maintenance. Herein, we summarize the miRNAs for which strong experimental
evidence supports their functional roles in AML pathogenesis. We also discuss the
implications of these studies on the development of miRNA-directed therapies in AML.
Keywords: microRNAs, leukemia, hematopoiesis, hematologic malignancies, leukemogensis
INTRODUCTION
Hematopoietic stem cells (HSCs) exhibit the unique ability to
undergo self-renewal and to give rise to all cells of the hematopoi-
etic system throughout the lifetime of an organism (Weissman,
2000; Kondo et al., 2003). In order for HSCs to maintain
hematopoiesis, the balance between self-renewal and differen-
tiation is ﬁnely regulated under both steady-state and stress
conditions. Several molecular networks that control these pro-
cesses have been identiﬁed in recent years (Ramalho-Santos et al.,
2002; Park et al., 2003; Zhang et al., 2006; Miyamoto et al., 2007;
Deneault et al., 2009; Hope et al., 2010; Aguilo et al., 2011; Ting
et al., 2012). As a part of this effort, microRNAs (miRNAs) have
been identiﬁed as regulators of HSC maintenance and lineage
commitment (Kluiver et al., 2007;Vasilatou et al., 2010). For exam-
ple, miR-223 regulates granulopoiesis (Fazi et al., 2005), miR-221
and miR-222 negatively control erythropoiesis (Felli et al., 2005),
and miR-146, miR-150, and miR-181 promote B-lymphocyte
development (Chen et al., 2004; Zhou et al., 2007; Cameron et al.,
2008).
Given the role of miRNAs in regulating normal hematopoiesis,
it is perhaps not surprising that miRNA misexpression may con-
tribute to the development of hematopoietic malignancies such
as acute myeloid leukemia (AML). AML consists of a heteroge-
neous group of malignancies characterized by the accumulation
of immature blasts and limited production of normal blood cell
components in the bone marrow (BM). While better supportive
care practices have mildly improved the prognosis of AML in the
past two decades, approaches to treat AML have remained essen-
tially unchanged. Thus, understanding the molecular mechanisms
regulating the pathogenesis of AML is of great interest.
The importance of miRNAs in carcinogenesis has been inferred
by their localization to genomic regions that are frequently deleted
or ampliﬁed, and to their presence near translocation breakpoints,
in various human cancers (Calin et al., 2004). The relevance of
miRNAs to hematologic malignancies was ﬁrst established when
miR-15 and miR-16 were shown to be the critical genetic ele-
ments deleted fromchromosome13q14 in a signiﬁcant proportion
of chronic lymphocytic leukemia (CLL) patients. In the con-
text of AML, gene expression proﬁling of AML patient blasts
revealed a widespread deregulation of miRNAs. These studies also
established associations between different miRNA signatures and
speciﬁc molecular subtypes of disease, suggesting their potential
role inAMLpathogenesis (Dixon-McIver et al., 2008; Garzon et al.,
2008a; Jongen-Lavrencic et al., 2008). The results of these studies
can be found in a number of previously published reviews (Kluiver
et al., 2006; Havelange et al., 2009; Vasilatou et al., 2010; Chung
et al., 2011).
While these gene expression analyses have been used to docu-
ment the transcriptional dysregulation of miRNAs in AML and
to identify potential diagnostic and prognostic miRNAs, they
have provided limited deﬁnitive evidence regarding the roles of
miRNAs in AML pathogenesis. In fact, few miRNAs have been
experimentally validated as mediators of initiation and/or main-
tenance of AML. In this review, we will focus our discussion on
miRNAs for which a functional link between miRNA dysregula-
tion and the development of AML has been established, including
miRNAs-125, -146, -155, -142, and -29.
miR-125
miR-125 is among one of the most extensively studied miRNAs
in the hematopoietic system. Members of the miR-125 family are
located in three highly conserved miRNA clusters throughout the
human genome. These clusters include miR-125a/miR-99b/let-7e,
miR-125b-2/miR-99a/let-7c-1, and miR-125b-1/miR-100/let-7a-2
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located on human chromosomes 19, 21, and 11, respectively. The
miR-125 family is highly conserved across species, with the same
clusters identiﬁed on chromosomes 17, 16, and 9 in the mouse
genome.
miR-125 IN HSC SELF-RENEWAL AND SURVIVAL
A number of groups have observed high expression of miR-
125 family members in HSCs and decreased expression during
myeloid differentiation, suggesting that miR-125 positively regu-
lates HSC function (O’Connell et al., 2010; Ooi et al., 2010; Gerrits
et al., 2012). O’Connell et al. (2010) ectopically expressed miR-
125b in human CD34+ cells and showed that this leads to a
signiﬁcant increase in the number of CD45+ cells and to the
expansion of human stem and progenitor cells (HSPCs) in the
bone marrow of xenotransplanted mice (O’Connell et al., 2010).
Similarly, Ooi et al. (2010) ectopically expressed miR-125b at levels
35-fold higher than endogenous levels via lentiviral transduc-
tion in mouse HSCs. Upon transplantation of these transduced
HSCs, recipient mice displayed increased numbers of HSCs,
but not of other immature hematopoietic cells, in both pri-
mary and secondary recipients. miR-125b overexpression was
also shown to reduce the levels of apoptosis in HSCs, a process
likely mediated through miR-125b inhibition of the pro-apoptotic
genes Klf13 and Bmf. Thus, these ﬁndings suggest that miR-125b
promotes HSC self-renewal by promoting HSC survival (Ooi
et al., 2010). Consistent with this prediction, overexpression of
miR-125b by 100-1000 fold in HSC-enriched bone marrow sig-
niﬁcantly improved engraftment in lethally irradiated recipients
(Gerrits et al., 2012). Similarly, Guo et al. (2010) described an 8-
fold increase in HSC number following enforced expression of
miR-125a. Lastly, 5-ﬂuorouracil (5-FU)-treated BM cells overex-
pressing miR-125a displayed increased HSC function as measured
by day-35 cobblestone-area forming cell (CAFC) activity and long-
term transplantation assays (Gerrits et al., 2012). Therefore, both
miR-125a and miR-125b appear to be potent mediators of HSC
self-renewal.
miR-125 IN HEMATOPOIESIS AND LEUKEMIA
miR-125b can act as a tumor suppressor or an oncogene depend-
ing upon tumor type. In breast cancer, miR-125b appears to act as
a tumor suppressor, as high levels of miR-125b inhibit the expres-
sion of the proto-oncogenic proteins ERBB2 and ERBB3 (Sonoki
et al., 2005; Bousquet et al., 2008). In contrast, in prostate can-
cer,miR-125b exhibits pro-oncogenic activity, with high miR-125b
expression inducing androgen-independent growth through the
negative regulation of Bak1, a pro-apoptotic Bcl2 family mem-
ber (Shi et al., 2007). In AML, miR-125b is strongly up-regulated
in patient blasts, and both in vivo and in vitro models sug-
gest that miR-125b can promote the transformation of normal
hematopoietic cells into malignant cells.
Insight into the biological effects of miR-125b comes from
both in vitro and in vivo ectopic expression studies. miR-125b
overexpression blocks terminal (monocytic and granulocytic) dif-
ferentiation in HL60 and NB4 AML cell lines (Bousquet et al.,
2008; Klusmann et al., 2010) and confers interleukin-3 (IL-
3) growth independence to the leukemic cell line, 32Dclone3
(Bousquet et al., 2012). ABTB1 and CBFB have been identiﬁed
as miR-125b targets that may mediate these anti-apoptotic and
pro-proliferative effects (Lin et al., 2011; Bousquet et al., 2012). In
vivo, primary recipients of HSCs overexpressing miR-125b (35-
fold) display myeloid-biased differentiation and expansion at the
expense of B cells, while secondary recipients develop a lym-
phoproliferative disease. This increase in lymphocyte output is
likely due to the preferential expansion of lymphoid-biased Slam−
HSCs, as they display intrinsically higher basal apoptotic rates,
whichmakes themmore prone tomiR-125’s anti-apoptotic effects.
Furthermore, a 35-fold overexpression of miR-125b was also asso-
ciatedwith an expansionof common lymphoidprogenitors (CLPs;
Ooi et al.,2010). Consistentwith these studies, enforced expression
of miR-125a in BM cells by 1000-fold enhanced long-term recon-
stitution of all blood lineages following transplantation. This effect
persisted in secondary transplants, although it was also associated
with increased myeloid cell output (Guo et al., 2010; Gerrits et al.,
2012). The majority of these mice also exhibited a myeloprolifera-
tive neoplasm (MPN)-like phenotype that occasionally progressed
to AML beginning ∼5 months post-transplant. The AML pheno-
typepersistedupon serial transplantation (Gerrits et al., 2012). In a
separate study, however, engraftment of HSCs ectopically express-
ing miR-125a declined over time in secondary recipients (Gerrits
et al., 2012), suggesting that miR-125a cannot maintain long-term
HSC self-renewal.
The pro-apoptotic gene, Bak1, was shown to be a bona ﬁde
target of miR-125a since its co-expression with miR-125a in 5-FU-
treated BM blocked hematopoietic expansion in vitro. However,
Bak1-null mice displayed a different hematopoietic phenotype,
suggesting that miR-125a targets multiple genes to produce the
myeloproliferative phenotype (Lindsten et al., 2000, 2003). In
another study,Lin28a, a known target of miR-125, was suggested to
partially mediate miR-125’s effects on lineage commitment since
knocking down Lin28a in bone marrow cells increased myeloid
cell number and reduced the number of B cells in mice, a phe-
notype reminiscent of the effects of miR-125b overexpression.
However, leukemia did not develop in mice transplanted with
Lin28a knockdown HSCs, suggesting that Lin28a is necessary, but
not sufﬁcient, for miR-125-driven leukemogenesis (Chaudhuri
et al., 2012).
The miR-125 overexpression studies have revealed numer-
ous phenotypes including lineage bias, enhanced HSC function,
and the induction of leukemia, raising questions regarding
the physiologic role of miR-125. It appears that the varying
phenotypes are likely due to differences in miR-125 expres-
sion levels. Mice transplanted with human fetal liver (FL) cells
expressing miR-125b at ∼1500-fold higher than endogenous
levels develop a MPN-like disorder, while slightly lower lev-
els of miR-125b expression (500-1000 fold) induce B- or T-cell
acute lymphoblastic leukemias (B-ALL, T-ALL; Bousquet et al.,
2010). Similarly, mice transplanted with 5-FU-treated BM cells
expressing approximately 100-fold higher levels of miR-125b-
1 and miR-125b-2 display expansion of all leukocyte lineages
including lymphocytes, while mice expressing miR-125b at signif-
icantly higher levels (500-1000 fold) develop a MPN-like disorder.
Although other experimental factors, such as starting HSPC
populations and methods of handling of HSCs in vitro dur-
ing viral transduction were not completely identical in these
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studies, the data suggest a strong gene dose:phenotype correla-
tion.
Consistent with miR-125b’s leukemogenic function, co-
transducing 5-FU-treated BM cells with miR-125b (overexpressed
500-fold) and the BCR-ABL fusion gene or mutant C/EBPα accel-
erated the development of leukemia (B-ALL, MPN, or mixed
leukemia with BCR-ABL, and myeloid leukemia with C/EBPα;
Bousquet et al., 2010; Enomoto et al., 2012). Furthermore, a num-
ber of studies have implicated miR-125b in the development of
acute megakaryocytic leukemia (AMKL), particularly in patients
with Down’s syndrome (DS). DS is characterized by trisomy 21;
miR-125b-2 is located on chromosome 21, and is expressed at
markedly higher levels in patients with AMKL (both DS and
non-DS related). Consistent with its role in determining the
differentiation characteristics of AMKL, ectopic expression of
miR-125b in K562 cells promotes megakaryocytic differentiation,
and enforced expression of miR-125b in megakaryocytic pro-
genitors (MPs) and megakaryocyte-erythroid progenitors (MEPs)
isolated from mouse E12.5 FL leads to increases in the size, fre-
quency, and re-plating capacity of megakaryocyte colony-forming
units (Klusmann et al., 2010).
To better understand the mechanism by which miR-125 pro-
motes megakaryocytic differentiation, investigators have studied
two miR-125b target genes, DICER1 and the tumor suppressor
ST18, both characterized as negative regulators of megakary-
opoiesis. Knocking down DICER1 or ST18 in FL cells leads
to megakaryocytic expansion, reminiscent of the phenotype
observed upon miR-125b overexpression. However, the expansion
was milder when compared to the miR-125b-driven phenotype,
suggesting that other miR-125b targets are likely involved in
this process. These studies also suggest that miR-125b aberrantly
induces self-renewal in fetal committed MPs and MEPs, as miR-
125b-2 overexpression in these cells causes them to continue to
proliferate in the presence of limited growth factors (e.g., TPO
alone) in liquid culture for >1 month. Similar results were
obtained using CD34+ cells from human cord blood (Klusmann
et al., 2010), but not adult bone marrow MEPs, suggesting that
miR-125 plays distinct roles in adult and fetal hematopoiesis. These
results provide a potential molecular basis for the robust asso-
ciation between DS and the development of AMKL, and likely
explains the higher incidence of AMKL in pediatric populations
relative to adults (Hasle, 2001).
In summary, the miR-125 family regulates self-renewal, both in
HSCs as well as fetal MP and MEPs. The variance in hematopoietic
phenotypes induced by miR-125 overexpression can be attributed,
in large part, to the level of overexpression, with lower levels
of miR-125 expression regulating hematopoietic differentiation
and proliferation and leading to myeloid (and sometimes T-cell)
expansion at the expense of B cells, while the highest levels induce
the development of aMPN-like phenotype that progresses toAML
(Table 1). The relevance of these studies to human disease is
worth considering, as miR-125 is upregulated by no more than
90-fold in myeloid malignancies (Bousquet et al., 2008). There-
fore, the high levels of miR-125 expression in these studies raise
concerns for possible non-physiologic and/or off-target effects
that may not entirely reﬂect miR-125’s normal biological con-
tribution to these processes. These concerns could be addressed
by developing miR-125 seed sequence mutants or through over-
expression at levels similar to that observed in patient samples.
In addition, complementary studies using additional knockdown
approaches [e.g., locked nucleic acids (LNA’s) and sponges], and
miR-125-targeted deletions could be used to determine whether
miR-125 is required for the development of leukemia in mouse
models and if it regulates the function of leukemic stem cells or
HSCs (Elmen et al., 2005; Ebert and Sharp, 2010; Chu et al., 2012).
Unfortunately, the presence of multiple miR-125 family mem-
bers and their potentially overlapping and/or redundant functions
make the generationof amiR-125-null mouse technically challeng-
ing. Finally, while the two miR-125 paralogs share the same seed
sequence, they differ in their mature sequence; thus, understand-
ing the target genes mediating the speciﬁc effects of miR-125a
and miR-125b will be an important area of investigation in the
future.
miR-146
miR-146a is located on chromosomes 5 and 11 in the human and
mouse genomes, respectively. Mature miR-146a is differentially
expressed during hematopoietic development, with relatively low
expression levels in HSPCs, and higher levels upon differentiation,
especially in activatedmacrophages andT-cells (Boldin et al., 2011;
Starczynowski et al., 2011;Yang et al., 2012), pointing to a potential
role in hematopoiesis. However, miR-146a is expressed ∼1.5-fold
higher in HSCs and in myeloid progenitors compared to other
progenitor subtypes (Zhao and Starczynowski, 2014). miR-146a
expression is regulated by several lineage-dependent transcription
factors including the myeloid-speciﬁc transcription factor, PU.1
(Jurkin et al., 2010; Ghani et al., 2011), and the megakaryocyte-
speciﬁc transcription factor, PLZF (Labbaye et al., 2008). In this
section,wewill focus on the role ofmiR-146a in the innate immune
system, myelopoiesis and the development of myelodysplastic
syndromes (MDS) and AML.
miR-146 AND INNATE IMMUNITY
miR-146a has been shown to both regulate, and be regu-
lated by, the NF-kB pathway, a critical mediator of inﬂamma-
tory signaling, cell survival, differentiation, and proliferation
(Silverman and Maniatis, 2001; Taganov et al., 2006; Hayden
and Ghosh, 2008; Figure 1). NF-kB positively regulates miR-
146a expression by binding two consensus-binding sites in the
miR-146a promoter (Taganov et al., 2006). In contrast, miR-
146a negatively regulates the NF-kB pathway by targeting of
two positive regulators of NF-kB, tumor necrosis factor receptor-
associated factor 6 (TRAF6) and IL-1 receptor-associated kinase-1
(IRAK1; Taganov et al., 2007; Figure 1). Consistent with miR-
146a’s negative regulation of NF-kB signaling,miR-146a knockout
mice display hypersensitivity in response to lipopolysaccharide
(LPS) challenge, as evidenced by signiﬁcantly elevated pro-
inﬂammatory cytokine production (Boldin et al., 2011). Thus,
miR-146a is an important negative regulator of innate immune
activation.
miR-146a AND NORMAL HEMATOPOIESIS
In normal hematopoiesis, miR-146a is a negative regulator of
megakaryopoiesis and granulocyte/macrophage differentiation.
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Table 1 | Summary of studies on miR-125 in hematopoiesis and leukemia.
miRNA Study Cell type 1◦ transplant 2◦ transplant Potential
targets
Timepoint
analyzed
Hematopoietic phenotype Timepoint
analyzed
Hematopoietic
phenotype
miR-125b Ooi et al. (2010),
PNAS
HSC 2.5 months 35X expression:
• Increased hematopoietic
stem cell (HSC) number
• Reduced HSC apoptosis
• GM expansion
• Reduced B cells
2.5 months • GM expansion
• Increased B cells
• Lymphoprolifera-
tive disease with
low penetrance
Pro-apoptotic
Klf13 and Bmf
miR-125b-1,
miR-125b-2
O’Connell et al.
(2010), PNAS
5-FU-treated
BM cells
2 months 100X expression:
• Expansion of all WBCs
including myeloid cells and
lymphocytes
500–1000X expression:
• Myeloproliferative disease
(MPD), as evidenced by
granulocyte/monocyte (GM)
expansion
• Reduced B cells,
• Reduced platelets and
RBCs,
• Splenomegaly
• Myeloid cell inﬁltration in
the liver
• Not investigated
miR-125b Bousquet et al.
(2008, 2010),
JEM, PNAS
Fetal liver
(FL) cells
4 months 500X expression:
•T-ALL
1000X expression:
• B-ALL
1500X expression:
• Myeloproliferative
neoplasm (MPN)
• Not investigated ABTB1, CBFB
miR-125a Guo et al.
(2010), PNAS
5 × 105 Total
BM
4 months 1000X expression:
• Enhanced reconstitution
• >8-fold HSC expansion
using limiting dilution
analysis
•The number of myeloid
cells predominated with a
reduced proportion of
lymphoid cells
5 months • Enhanced
reconstitution
Pro-apoptotic
Bak1
miR-125a Gerrits et al.
(2012), Blood
5–10 × 106
5-FU-treated
BM cells
2.5–5 months 1500X expression:
• Increased stem cell
number
•The number of GM and
T-cells predominated with a
reduced proportion of B
lymphoid cells
1.5–6 months • Unlike Guo et al.
(2010), reduced
engraftment of
HSCs
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FIGURE 1 | Proposed model for the effect of miR-146a deficiency in
the pathogenesis of del(5q) myelodysplastic syndromes (MDS). Loss
of one copy of miR-146a results in a decrease in its inhibitory effect on
tumor necrosis factor receptor-associated factor 6 (TRAF6 ).
TRAF6-mediated increase in IL-6 expression leads to autocrine and
paracrine effects on HSPCs. Moreover, while TRAF6 exerts autocrine
anti-apoptotic roles in HSPCs, it leads to increased apoptosis in a
paracrine manner. Thus, these observations could provide a possible
mechanism for the observed bone marrow hypercellularity in MDS bone
marrows, despite the presence of increased overall apoptosis.
Downstream mediators of TRAF6 leading to these effects are currently
under investigation.
Labbaye et al. (2008) showed that miR-146a is downregulated
during megakaryopoiesis and that this downregulation is impor-
tant for normal megakaryopoiesis. Overexpressing miR-146a in
human CD34+ cells impaired megakaryocytic proliferation, dif-
ferentiation, and maturation in vitro, while knocking down
miR-146 reversed this phenotype. These phenotypes appear to be
mediated by at least two mechanisms: (i) circumventing the neg-
ative regulation of miR-146a by PLZF, a megakaryocytic lineage
promoting transcriptional repressor, that binds to the miR-146a
promoter (Labbaye et al., 2002), and (ii) directly inhibitingCXCR4,
which is indispensible for megakaryopoiesis and contains a 3′UTR
miR-146a binding site (Avecilla et al., 2004). Together, these studies
suggest that megakaryopoiesis is controlled by the PLZF suppres-
sion of miR-146a, which in turn relieves the inhibition of CXCR4
by miR-146a. In support of this model, Starczynowski et al. (2010)
showed that knocking down miR-146 using a miRNA decoy sys-
tem in mouse HSPCs increased megakaryopoiesis in vivo through
a TRAF6-dependent pathway, and that overexpressing TRAF6
in mouse bone marrow cells resulted in a similar phenotype
(Figure 1).
Despite these data supporting a negative role for miR-146a
in megakaryopoiesis, other studies have generated contradictory
results. For instance, Opalinska et al. (2010) showed that overex-
pressing miR-146a in mouse HSCs fails to alter megakaryocyte
development or platelet production in vivo and in vitro; these
ﬁndings were conﬁrmed in a separate study by Starczynowski
et al. (2011). These conﬂicting results may stem from the atten-
uation of miRNA inhibition in the presence of abundant target
transcripts, which has been previously described in other con-
texts (Arvey et al., 2010). As such, miR-146a expression may be
sufﬁciently high in HSCs for maximal target gene inhibition;
thus ectopic expression of miR-146a would not be expected to
induce a substantial phenotypic change, while knocking down
miR-146a would still be expected to release its inhibition of TRAF6
and increase megakaryopoiesis, consistent with early ﬁndings of
Starczynowski et al. (2010). Alternatively, the effect of miR-146a
may be context-speciﬁc, since miR-146a overexpression in human
HSPCs, speciﬁcally, has been shown to impair megakaryocytic
differentiation (Labbaye et al., 2008). Bioinformatic approaches
assigning miR-146a “inhibition indices” to its key target gene(s)
(e.g., TRAF6) in human and mouse HSPCs might help resolve
these paradoxical results (Arvey et al., 2010).
While miR-146a seems to a play a role in normal megakary-
opoiesis, it also appears to be a negative regulator of granulo-
cyte/macrophage differentiation in the context of aging. miR-
146a-null mice display no detectable hematopoietic phenotypes
under normal conditions during the ﬁrst 2 months of life. While
the absence of such a phenotype might be explained, in part, by
compensatory effects of other members of the miR-146 family,
it might also be explained by a model in which miR-146a exerts
www.frontiersin.org November 2014 | Volume 5 | Article 361 | 5
Khalaj et al. microRNA’s in AML/MDS
its effects under non-homeostatic and/or stress conditions. Con-
sistent with the latter, miR-146a-null mice produce increased
numbers of granulocyte/monocyte (GM) cells with advancing
age (Boldin et al., 2011). Such GM expansions have also been
detected in young miR-146a-null mice upon repeated exposure
to LPS (Zhao et al., 2013), suggesting that chronic inﬂamma-
tion may contribute to the myeloproliferative phenotype observed
in aging miR-146-null mice. Furthermore, overexpressing miR-
146a in young HSPCs results in opposite effects on granulopoiesis
in young mice, suggesting that miR-146a functions as a tran-
sient positive regulator of myelopoiesis in young mice (Opalinska
et al., 2010; Starczynowski et al., 2011). Consistent with this,
transplantation of miR-146a knockdown HSPCs into lethally irra-
diated mice results in mild neutropenia (Starczynowski et al.,
2010).
In addition to its regulation of myelopoiesis, miR-146a plays a
role in HSC maintenance. miR-146a-null mice harbor decreased
numbers of CD150+CD48− LT-HSCs by 8 months of age and
HSC exhaustion by 12 months. In addition, a functional decline in
HSCs is apparent as early as 2 months of age in competitive repop-
ulation assays. These effects are predominantly cell-intrinsic since
transplanting WT HSCs into miR-146a-null and normal donors
results in minor differences. Intriguingly,miR-146a-deﬁcient lym-
phocytes display a hyper-activated phenotype with dysregulated
cytokine production, suggesting a lymphocyte-mediated mecha-
nism for the reduction of HSC numbers. To test this possibility,
miR-146a and Rag1, a gene required for lymphocyte maturation,
were simultaneously deleted, leading to a partial rescue of the
HSC exhaustion and the myeloproliferative phenotypes observed
in miR-146a-null mice (Zhao et al., 2013). These ﬁndings are con-
sistent with the systemic autoimmunity observed in some MDS
patients (Nimer, 2008).
miR-146a AND MYELOID MALIGNANCIES
miR-146a is located within the common deleted region (CDR)
of del(5q) MDS. This deletion is associated with signiﬁcantly
reduced levels of miR-146a in human bone marrow cells com-
pared to other subtypes of MDS. Similar reductions in expression
are also observed with miR-145, which is also present in the 5q
CDR (Starczynowski et al., 2010). To elucidate the role of these
miRNAs in MDS, Starczynowski et al. (2010) knocked down miR-
146a and miR-145 in mouse HSPCs and transplanted them into
lethally irradiated mice. Eight weeks following transplantation,
recipient mice exhibited thrombocytosis, variable neutropenia,
and hypolobated megakaryocytes in the bone marrow—all fea-
tures observed in human del(5q) MDS patients. Using luciferase
reporter assays, TIRAP and TRAF6 were identiﬁed as target genes
of miR-145 and miR-146a, respectively. In order to determine
whether TRAF6 is a mediator of the del(5q) MDS pheno-
type, TRAF6 was overexpressed in mouse bone marrow cells
and transplanted into recipient mice. By 12 weeks, the recipi-
ent mice developed neutropenia, thrombocytosis, and increased
hypolobated megakaryocytes in the bone marrow, and most
progressed to bone marrow failure or AML at ≥5 months
post-transplantation. In addition, knocking down miR-146a in
TRAF6-null cells failed to increase megakaryocyte colony for-
mation in vitro. Similarities between the TRAF6-induced mouse
hematopoietic phenotype and human del(5q) MDS strongly sug-
gest that down-regulation of miR-146a in HSPCs plays a critical
role in the development of MDS, largely by inhibiting TRAF6.
As TRAF proteins are key intermediaries in the activation of
canonical NF-kB signaling pathway (Bradley and Pober, 2001),
these data suggest that NF-kB may be downstream of miR-146a
and responsible for mediating a signiﬁcant part of the miR-146a
phenotype. Support for this model was provided by experi-
ments in which the NF-kB p50 subunit was knocked down and
conﬁrmed to rescue some aspects of the myeloproliferative phe-
notype of miR-146a-null mice (Zhao et al., 2011). Nevertheless,
other signaling pathways, including non-canonical NF-kB path-
ways, contribute to the miR-146a phenotype as well (Etzrodt
et al., 2012). For instance, TRAF6 is known to regulate addi-
tional signaling pathways through its E3 ubiquitin ligase domain
(Yang et al., 2009). Future studies are needed to identify path-
ways regulated by this activity of TRAF6 in miR-146a-deﬁcient
HSPCs.
The co-occurrence of peripheral blood cytopenias with bone
marrow hypercellularity and apoptosis is frequently observed in
MDS (Boldin et al., 2011; Zhao et al., 2011). To explain this appar-
ent paradox, it has been proposed that the increase in apoptosis is
counterbalanced by a simultaneous increase inHSPCproliferation
(Lepelley et al., 1996). This possibility was investigated in TRAF6-
mutant mice that had progressed to bone marrow failure or AML.
Non-TRAF6 transduced regions of the bone marrow exhibited
elevated levels of apoptosis relative to transduced regions. This
ﬁnding raises the possibility that TRAF6 protects HSPCs from
cell death in a cell autonomous manner while simultaneously
promoting apoptosis in non-TRAF6-expressing cells in a non-
autonomous manner (Figure 1). Furthermore, megakaryocyte
expansions observed in both the transduced and non-transduced
cells in mice transplanted with miR-146a knockdown cells sug-
gest a potential paracrine mechanism inducing thrombocytosis
(Figure 1). To investigate this possibility, cytokines and growth
factors involved in megakaryopoiesis were measured. Increased
circulating IL-6, but not other cytokines, was detected in the
serumof miR-146a-chimericmice (Kishimoto, 2005). Concurrent
transduction of dominant-negative TRAF6 into mouse HSPCs
reversed the phenotype, indicating that IL-6 induction by miR-
146a knockdown is mediated through TRAF6. Interestingly, the
leukemogenic activity of TRAF6 was not affected when overex-
pressed in IL-6-null HSPCs, suggesting that a non-IL-6 dependent
mechanism mediates the role of TRAF6 in the development of
leukemia.
Additionally, the role of miR-146a as a tumor suppressor in
MDS is supportedby thedevelopment of pancytopenia andmyelo-
proliferation involving the spleen, bone marrow, and secondary
lymphoid organs in aging miR-146-null mice. Consistent with
its negative regulation of myeloproliferation, miR-146a-null BM
derived macrophages (BMDM) exhibit increased rates of prolif-
eration, likely due to elevated levels of M-CSF receptor (CSF1R)
expression and M-CSF signaling (Boldin et al., 2011).
In summary, miR-146a regulates HSC maintenance as well
as megakaryocytic differentiation. It also regulates GM differ-
entiation in an age-dependent manner. Moreover, miR-146a
down-regulation contributes to the development of del(5q) MDS
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and promotes disease progression to AML through the TRAF6-
mediated induction of NF-kB and apoptosis. Additional studies
are necessary to elucidate the relative contribution of miR-146a to
del(5q) MDS pathogenesis by investigating the potential additive
or synergistic effects of miR-146awith other genes located in the 5q
deleted region (e.g., ribosomal protein RPS14; Ebert et al., 2008)
using both mouse models and primary MDS patient samples.
miR-155
Human miR-155, located on human chromosome 21, resides in
a spliced and polyadenylated non-coding RNA transcript called
the B-cell integration cluster (BIC; Tam, 2001). BIC is an evo-
lutionarily conserved RNA that was initially shown to cooperate
with c-Myc to induce lymphomas in chickens when aberrantly
activated by pro-viral integrations at a common retroviral inte-
gration site (Tam et al., 1997; Tam and Dahlberg, 2006). More
recently, studies suggest that miR-155 may also play a role in
mediating leukemogenesis. While the mechanisms underlying the
transformative activity of this non-coding RNA were a mystery
for some time, it has now become clear that BIC contains the pre-
miR-155 sequence and that it mediates its oncogenic functions
by giving rise to the mature miR-155 transcript (Lagos-Quintana
et al., 2002; van den Berg et al., 2003; Eis et al., 2005; Kluiver
et al., 2005). In this section, we will review studies that have
established a role for miR-155 in the pathogenesis of myeloid
malignancies.
miR-155 IN NORMAL AND MALIGNANT MYELOPOIESIS
During steady state hematopoiesis, miR-155 is expressed at high
levels in HSPCs and at low levels in most mature hematopoietic
cells; for example, miR-155 is expressed at high levels in ery-
throblasts relative to maturing erythroid progenitors (Georgantas
et al., 2007; Masaki et al., 2007; O’Connell et al., 2008). Moreover,
miR-155 expression increases during B- (Tam, 2001; van den Berg
et al., 2003; Eis et al., 2005; Tam and Dahlberg, 2006; Masaki et al.,
2007; Garzon et al., 2008b) and T-cell activation (Rodriguez et al.,
2007), and upon exposure of innate immune cells (e.g. mono-
cytes) to inﬂammatory stimuli such as LPS (Gorgoni et al., 2002;
Hayden and Ghosh, 2008; O’Connell et al., 2009). The latter likely
explains miR-155’s role in mediating innate immune responses
(Georgantas et al., 2007).
Overexpressing miR-155 in HSCs leads to the expansion of
GM cells, extramedullary hematopoiesis, and the development of
GM cells with morphologic dysplasia in C57BL/6 mice, compati-
ble with a myeloproliferative-like disorder (Garzon et al., 2008a,b;
Jongen-Lavrencic et al., 2008). miR-155 is also expressed at low
levels in mature erythroid cells, and overexpression of miR-155 in
HSCs is associated with a reduction in Ter119+ erythroid progen-
itors in the mouse bone marrow. This latter ﬁnding is consistent
with observations in human CD34+ cells overexpressing miR-
155 (Georgantas et al., 2007). miR-155 may concurrently inhibit
megakaryopoiesis, as miRNA-155-transduced K562 cells treated
with hemin, an inducer of megakaryocytic differentiation, exhibit
reduced expression of CD41 (Georgantas et al., 2007). While these
studies collectively indicate that miR-155 regulates myeloid lin-
eage commitment, the mechanisms by which miR-155 exerts its
effects – whether by negatively regulating apoptosis, promoting
commitment to the common myeloid progenitor (CMP) lineage
inHSPCs, or by increasing the rate of proliferation amongmyeloid
progenitors or their maturing progeny – remains unresolved and
will need to be explored in future studies.
Consistent with ectopic overexpression of miR-155 induc-
ing a myeloproliferative phenotype, several studies have shown
the upregulation of miR-155 in the bone marrow of NPM1
and FLT3-ITD-mutant AML patients (Garzon et al., 2008a,b;
Jongen-Lavrencic et al., 2008). It is also possible that the miR-
155 myeloproliferative phenotype was observed due to the effects
of miR-155 overexpression being only assessed in the transplan-
tation setting, which requires lethal irradiation, the induction of
strong inﬂammatory responses, and the up-regulation of miR-
155 expression in the bone marrow of recipient mice. Consistent
with this idea, altered myeloid phenotypes have not been observed
in the bone marrow or peripheral blood of miR-155-null mice
(Rodriguez et al., 2007).
MECHANISM OF ACTION OF miR-155
To determine which miR-155 target genes are required to induce
the miR-155 overexpression phenotype, O’Connell et al. (2008)
overexpressed miR-155 in RAW 264.7 myeloid cells and showed
reductions in the transcripts of several genes (Bach1, Sla, Cutl1,
Csf1r, Jarid2, Cebpβ, PU.1, Arntl, Hif1α, and Picalm) known
to play critical roles in hematopoiesis; subsequent studies have
established that miR-155 directly inhibits src homology 2 domain-
containing inositol-5-phosphatase (SHIP1) as well as CCAAT-
enhancer-binding protein-beta (CEBP-β) to mediate leukemoge-
nesis (Gorgoni et al., 2002; O’Connell et al., 2009). The functional
link between SHIP1 and miR-155 was strongly suggested by show-
ing that knocking down SHIP1 or overexpressing miR-155 in
HSPCs induces similar myeloproliferative phenotypes character-
ized by increased numbers of CD11b+ myeloid cells in the bone
marrow and spleen, decreased erythropoiesis in the bone marrow,
and splenomegaly (O’Connell et al., 2009). In contrast to miR-155,
which may require previous irradiation to mediate myeloprolifer-
ation, SHIP1-null mice display a myeloproliferative phenotype in
the absence of stress/inﬂammatory stimuli. This is likely due to
higher baseline levels of cell-intrinsic inﬂammation in SHIP1-null
mice as they are hyper-responsive to cytokine stimulation in vitro
(Helgason et al., 2000) due to the loss of SHIP1’s negative regu-
lation of cytokine signaling (Kalesnikoff et al., 2003; Leung et al.,
2009). This functional interaction is of great interest since SHIP1
was previously shown to be a tumor suppressor inAML (Luo et al.,
2003).
SHIP1 is a phosphatase that mediates the conversion of
phosphatidylinositol triphosphate (PIP3) to phosphatidylinositol
diphosphate (PIP2). PIP3 normally acts as a docking site for sig-
naling molecules in the PI3K-Akt pathway (e.g., Akt and PLC) and
helps relay the signal (Figure 2). Thus, SHIP1 blocks the activation
of the PI3K-Akt pathway (Damen et al., 1996; Ono et al., 1996).
SHIP1’s ability to suppress the development of AML is probably
mediated through this pathway (Luo et al., 2003). Since SHIP1 has
been shown to negatively regulate PI3K/Akt signaling, it would be
interesting to investigate whether miR-155-induced phenotypes
depend on the activation of this pathway. Moreover, in these
studies, the phenotypes of SHIP1 and miR-155 were investigated
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FIGURE 2 | Proposed mechanism for miR-155-mediated myeloid
leukemogenesis. Overexpression of miR-155 leads to the activation of
the PI3K-Akt pathway through negative regulation of Src Homology 2
domain-containing Inositol-5-Phosphatase (SHIP1). SHIP1 is a
phosphatase that mediates the conversion of phosphatidylinositol
triphosphate (PIP3) to phosphatidylinositol diphosphate (PIP2). PIP3
normally acts as a docking site for signaling molecules in the PI3K-Akt
pathway and helps relay the signal. Upon miR-155 overexpression and
thus, SHIP1 downregulation, PIP3 level is increased, which leads to
the activation of the PI3K-Akt pathway. Green arrows indicate
increased, and red arrows decreased activity upon miR-155
overexpression.
independently. However, the importance of SHIP1 in the miR-155
overexpression phenotype has not been explored by testing the
ability of miR-155 to induce phenotypes in the context of SHIP1
loss-of-function or deﬁciency. It is also unclear at which stage
of hematopoietic development the miR-155:SHIP1 interaction is
required to induce these phenotypes. It would presumably be in
an early progenitor population based on miR-155’s high levels of
expression in HSPCs.
Another miR-155 target gene, CEBP-β, appears to ensure that
the hyperproliferation under stress ismyeloid in nature. CEBP-β is
a transcription factor involved in macrophage activation and the
induction of pro-inﬂammatory cytokines and acute phase reac-
tants (Gorgoni et al., 2002). In one study, LNA-induced in vivo
silencing of miR-155 in the splenocytes of LPS-treated mice led
to the de-repression of CEBP-β compared to LNA-control LPS-
treatedmice. Moreover, antagonismofmiR-155 in anAMLcell line
was also accompanied by a reduction in the inﬂammatory cytokine
G-CSF (Worm et al., 2009). These ﬁndings suggest that miR-155
overexpression inducesGMexpansion by targetingCEBP-β. How-
ever, it is unclear whether such a reduction in G-CSF production
is dependent on CEBP-β, SHIP1, or both. We speculate that it is
likely mediated through SHIP1 since SHIP1-deﬁcient mice have
been shown to exhibit increased G-CSF production (Figure 2;
Hazen et al., 2009).
Interestingly, miR-155-mediated hematopoietic malignancies
exhibit longer latencies compared to more aggressive miRNA
leukemia models, such as those induced by miR-125 overexpres-
sion. This raises the possibility that additional mutations are
required for full transformation. Intriguingly, miR-155 targets
mismatch repair genes such as hMLH1, hMSH2, and hMSH6
(Valeri et al., 2010), as well as cell-cycle regulators such as WEE1
(Tili et al., 2011). Thus, miR-155 may increase spontaneous muta-
tion rates inHSPCs, in agreement with observationsmade in some
solid tumor cell lines (Mantovani et al., 2008;Valeri et al., 2010; Tili
et al., 2011). It would be interesting to investigate this hypothesis
in the context of AML and to determine whehter such mutations
are required for the full manifestation of disease phenotypes.
While the cumulative data indicate that miR-155 can initiate
early events in myeloid leukemogenesis, it is not clear whether
miR-155 is required for leukemic progression or maintenance.
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Knocking down miR-155 in fully transformed AML cells or
reversibly expressing miR-155 in a progressive model of AML
would help address these important questions. If miR-155 can
be shown to regulate disease maintenance or resistance to therapy,
it would be an excellent target in the treatment of AML.
miR-142
miR-142 is located on human chromosome 17. While miR-142
is expressed in all hematopoietic tissues including the bone mar-
row, spleen and thymus, it is not expressed in non-hematopoietic
tissues. Perhaps it is not surprising that the ﬁrst role ascribed
to miR-142 was in promoting the development of the T-cell and
myeloid lineages (Chen et al., 2004). miR-142’s importance as a
regulator of hematopoiesis was recently underscored by the fact
that it is the only miRNA that is recurrently mutated in AML
(Cancer Genome Atlas Research Network, 2013).
miR-142 IN NORMAL AND MALIGNANT HEMATOPOIESIS
miR-142 regulates normal hematopoiesis as well as the devel-
opment of lymphoid and myeloid leukemias. By enforcing
the expression of miR-142 in Lin− mouse bone marrow cells,
Chen et al. (2004) showed that miR-142 increases the abso-
lute numbers of T-cells, leads to a minimal decrease in B-cell
differentiation (CD19+), and slightly reduces the number of
Mac1+ Gr1− myeloid cells. miR-142 also appears to play a
role in the development of mature lymphoid malignancies, as
the miR-142 locus is 50bp from the breakpoint of t(8;17), a
cytogenetic alteration present in a subset of aggressive mature
B-cell leukemias (Gauwerky et al., 1989). This suggests that
MYC, located on chromosome 8, is translocated and regu-
lated by the upstream miR-142 promoter (Lagos-Quintana et al.,
2002). Interestingly, miR-142-3p is signiﬁcantly downregulated
in ALL patients expressing the MLL-AF4 fusion gene. Ectopic
expression of miR-142-3p in MLL-AF4+ cell lines supresses
cell proliferation, induces apoptosis, and down-regulates mul-
tiple genes known to regulate self-renewal including MLL-AF4,
HOXA9, HOXA7, and HOXA10. Thus, miR-142-3p likely func-
tions as a tumor suppressor in MLL-AF4+ ALL (Dou et al.,
2013).
In addition to its role in lymphopoiesis and lymphoid malig-
nancies, miR-142 also regulates myeloid differentiation and the
development of AML. It is up-regulated during myeloid differen-
tiation in both normal and leukemic HSPCs. Overexpressing miR-
142 promotes phorbol-12-myristate-13-acetate (PMA)-induced
monocytic and all-trans retinoic acid (ATRA)-induced granu-
locytic differentiation in AML cell lines by directly targeting
the cyclin T2 (CCNT2) and “TGFβ–activated kinase 1/MAP3K7
binding protein 2” (TAB2) transcripts. In addition, miR-142-3p
levels are signiﬁcantly reduced in CD34+ cells from primary
AML samples. This decrease is associated with the increased
expression of CCNT2 and TAB2, two predicted miR-142 tar-
gets. Conversely, enforced expression of miR-142-3p in HSPCs
from healthy controls and AML patients down-regulates the
expression of CCNT2 and TAB2 and promotes myeloid differ-
entiation (Wang et al., 2012b). Thus, reductions in miR-142-3p
likely result in the differentiation blockade that is characteris-
tic of AML. In support of this model, independent expression
proﬁling studies revealed that miR-142-3p is down-regulated in
peripheral blood mononuclear cells (PBMCs) from AML patients
(Wang et al., 2012a). Furthermore, higher miR-142 expression
correlates with a better prognosis in patients with intermediate-
risk AML (Wang et al., 2012b; Dahlhaus et al., 2013). Perhaps
the most compelling evidence supporting the role of miR-142-
3p in leukemogenesis comes from RNA-sequencing studies of
AML. Of the samples examined, 7/200 (3.5%) harbored muta-
tions in miRNAs, of which 4/7 (57%) were present in the seed
sequence of miR-142-3p. Other non-recurrent mutations identi-
ﬁed in miRNAs were found in miR-516b1, miR-1267, miR-891a,
and miR-632. Additional studies will be required to elucidate
how miR-142 and other mutated miRNAs contribute to AML
pathogenesis. This is particularly important because the novel
seed sequences generated are predicted to alter target speciﬁcity
and it is unclear whether these mutations are loss- and/or gain-
of-function in nature (Cancer Genome Atlas Research Network,
2013).
miR-29
miR-29 family members have been shown to function both as
tumor suppressors and oncogenes in myeloid malignancies. The
miR-29 family consists of three members, miR-29a, miR-29b, and
miR-29c. The miR-29a/miR-29b-1 and miR-29b-2/miR-29c clus-
ters are present on chromosomes 7q32 and 1q23, respectively
(Hwang et al., 2007; Garzon et al., 2009a). In this section, we
describe the role of miR-29 in regulating epigenetic modiﬁers, cel-
lular proliferation, apoptosis, and hematopoietic differentiation,
and the role of these functional changes in AML pathogenesis.
miR-29 AND EPIGENETIC REGULATION
Myeloid malignancies frequently exhibit epigenetic alterations,
and subsets of patients with MDS, MPN, and AML have been
shown to harbor activating mutations and loss-of-function muta-
tions in master epigenetic regulators such as DNA methyltrans-
ferase 3 (DNMT3) and TET-eleven translocation 2 (TET2);
the combination of these mutations account for 33% of the
somatic mutations identiﬁed in AML (Delhommeau et al., 2009;
Langemeijer et al., 2009; Tefferi et al., 2009a,b,c; Patel et al., 2012).
Interestingly, the up-regulation of DNMT transcripts (including
DNMT1, 3A, and 3B) and reductions in TET2 enzymatic activity
have been identiﬁed in patients harboring wild-type DNMT and
TET2, suggesting that their activity is regulated by transcriptional
and post-transcriptional regulatory mechanisms (Mizuno et al.,
2001; Ko et al., 2010). In a subset of these patients, IDH mutations
are likely to account for the dysregulation of TET2 activity, while
other unidentiﬁed factors also likely alterTET2 activity (Shih et al.,
2012).
The down-regulation of miR-29b is thought to promote DNA
hypermethylation in AML since miR-29b can directly target
DNMT3A, DNMT3B, and Sp1 (a transcriptional regulator of
DNMT1; Figure 3A; Garzon et al., 2009b). This link between miR-
29 expression and methylation status in AML cells prompted the
evaluation of miR-29b as a therapeutic target inAML. Investigators
have shown that miR-29b oligonucleotide mimics recapitulate the
effects of hypomethylating agents, 5-azacytidine and decitabine,
by demethylating the promoters of tumor suppressors estrogen
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FIGURE 3 | miR-29 family members target multiple genes to
mediate their biologic effects. (A) miR-29 directly targets DNA
methyltransferase 3 (DNMT3a) and DNMT3b, and indirectly targets
DNMT1 by down-regulating Sp1, to mediate global DNA hypomethylation
in acute myeloid leukemia (AML) cells. (B) miR-29 targets TET -eleven
translocation (TET) family members, TET1, TET2, and TET 3, which may
or may not mediate global DNA hypermethylation. The down-regulation
of TETs induces aberrant self-renewal and the development of
myeloproliferative neoplasm (MPN’s). (C) miR-29 targets cyclin T2
(CCNT2) and CDK6 to promote myeloid differentiation. (D) miR-29
promotes the down-regulation of c-Kit during normal hematopoiesis.
However, the down-regulation of miR-29 in malignant hematopoiesis
promotes c-kit-driven AML by up-regulating Sp1, which increases c-Kit
expression and suppresses miR-29 expression.
receptor 1 (ESR1) and p15INK4b, and by promoting the re-
expression of these genes in AML cell lines (Garzon et al., 2009b).
These results indicate that miR-29b oligonucleotides may be an
effective therapeutic strategy in the treatment of AML.
In contrast to DNMTs, which methylate CpG islands and
generally mediate transcriptional suppression, TET family mem-
bers (TET1, TET2, and TET3) demethylate DNA by catalyzing
the conversion of 5-methylcytosine (5mC) into intermediates of
DNA methylation, including 5-hydroxymethylcytosine (5hmC),
5-formylcytosine (5fC), and/or 5-carboxylcytosine (5caC; He
et al., 2011; Ito et al., 2011). Cheng et al. (2013) found that over-
expressing any of the three miR-29 family members in mouse
bone marrow cells reduced the level of TET2 as well as its
metabolic by-product, 5hmC (Figure 3B). The reduction in 5hmC
was rescued by ectopically expressing TET2. Of note, however,
reductions in 5hmC levels in the wild-type mice transplanted
with miR-29b-transduced bone marrow cells were attributed to
global DNA hypermethylation, while direct evaluation of the
global DNA methylation (GDM) status of these cells was not
performed. Performing mass spectrometry on miR-29 overex-
pressing cells and evaluating whether the reductions in 5hmC
correlate with increases in GDM are critical, as studies identifying
reduced 5hmC as a surrogate for global DNA hypomethylation
have yielded conﬂicting results (Ko et al., 2010; Shih et al., 2012).
It would also be interesting to evaluate the levels of the DNMTs,
TETs, and GDM simultaneously upon miR-29 overexpression
in leukemic blasts and normal HSPCs. This would help eluci-
date whether the effect of miR-29 on DNMTs and TETs are cell
context-speciﬁc, or whether DNMTs and TETs function to pro-
mote the methylation and demethylation of distinct target genes
simultaneously.
miR-29 AND MYELOID DIFFERENTIATION
Numerous studies have demonstrated that miR-29 family mem-
bers are regulators of myeloid differentiation. Han et al. (2010)
showed that transplanting mice with HSPCs overexpressing miR-
29a results in increased myeloid and reduced lymphoid chimerism
8–12 weeks post-transplant, and is accompanied by splenomegaly
as well as megakaryocytic and granulocytic hyperplasia in the
bone marrow and spleen, consistent with a myeloproliferative
phenotype. Similarly, Wang et al. (2012b) reported that miR-29a
expression increases with PMA-induced monocytic differentia-
tion and ATRA-induced granulocytic differentiation in AML cell
lines. The latter study showed that the increase in miR-29a expres-
sion was associated with reductions in CDK6 levels upon myeloid
differentiation and reductions in CCNT2 upon monocytic dif-
ferentiation. In this study, CCNT2 and CDK6 were shown to be
authentic targets of miR-29a, and their reduced expression was
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necessary and sufﬁcient for enhanced PMA and ATRA-induced
myeloid differentiation. These ﬁndings were validated in human
samples, as miR-29a overexpression partially reversed the differ-
entiation arrest phenotype in primary AML blasts. Moreover,
enforced expression of miR-29a in healthy CD34+ cells pro-
moted monocytic and granulocytic differentiation (Wang et al.,
2012b). These ﬁndings indicate that miR-29a regulates myeloid
differentiation, at least partially through the targeting of CCNT2
and CDK6 (Figure 3C). Additional studies have shown that
overexpressing another member of the miR-29 family, miR-29b,
promoted partial differentiation of an AML cell line, while both
miR-29b and miR-29c promoted myeloid differentiation in AML
patient CD34+ blasts (Fujimoto et al., 2007; Garzon et al., 2009b;
Cheng et al., 2013; Gong et al., 2014). Furthermore, transplanting
mouse bone marrow cells overexpressing miR-29b led to biased
myeloid differentiation, splenomegaly, and an increased percent-
age of donor-derived monocytes in the bone marrow, inducing a
chronic myelomonocytic leukemia (CMML)-like disease (Cheng
et al., 2013). Given these ﬁndings, it would be interesting to deter-
mine whether miR-29 oligonucleotides can act synergistically with
ATRA, arsenic trioxide, or ATRA-arsenic trioxide combinations in
primary AML patient blasts to evaluate the potential therapeutic
efﬁcacy of miR-29 mimics in the treatment of acute promyelo-
cytic leukemia (APL). Combinatorial regimens including miR-29
with cytarabine and/or daunorubicin could also help elucidate its
therapeutic efﬁcacy as a stimulant of myeloid differentiation in
non-APL myeloid leukemias.
miR-29 IN CELLULAR PROLIFERATION AND APOPTOSIS
In addition to their roles in epigenetic regulation and differen-
tiation, miR-29a and miR-29b have been shown to regulate a
number of cellular processes. A transcriptomal analysis of human
leukemia cell lines transfected with synthetic miR-29b revealed
the enrichment of genes that regulate apoptosis, cell cycle pro-
gression, and cellular proliferation. Altered expression of some of
these genes (e.g., MCL-1 and CDK6) was conﬁrmed in primary
AML blasts following transfection with miR-29b mimics (Garzon
et al., 2009a). These changes were also accompanied by a reduc-
tion in phosphorylated Rb (pRb) due to the miR-29 targeting of
CDK6 and CCNT2. Similar ﬁndings were generated by Gong et al.
(2014), who showed that overexpressing miR-29 family members
in AML cell lines stimulates apoptosis and inhibits the G1 to S
phase cell cycle transition, phenotypes attributed to the miR-29
targeting of CCND2 and AKT2 (Gong et al., 2014; Figure 3D). In
contrast, Han et al. (2010) found that overexpressing miR-29a in
293T cells enhanced cell cycle entry without altering apoptosis.
In addition, mice overexpressing miR-29a demonstrated a devel-
opmental stage-speciﬁc increase in proliferation, as multipotent
progenitors (MPPs) showed increased numbers of cycling cells
while more committed GMP and CMPs did not (Han et al., 2010).
These ﬁndings suggest that the cellular consequences of miR-29
overexpression are cell-type speciﬁc and may depend on the state
of differentiation and/or transformation.
miR-29 AS AN ONCOGENE AND TUMOR SUPPRESSOR
While overexpression studies in leukemic cell lines have shown that
miR-29 family members are able to regulate leukemic cell growth
and survival, other studies have revealed the leukemogenic poten-
tial of the miR-29 family. Han et al. (2010) showed that CMPs
and GMPs from mice overexpressing miR-29a establish long-
term, differentiating grafts in transplantation studies, suggesting
that miR-29a overexpression is sufﬁcient to induce aberrant
self-renewal in CMPs and GMPs, but not a fully transformed phe-
notype. Mice serially transplanted with bulk splenocytes or bone
marrow cells from these miR-29a overexpressing mice developed
organomegaly and increased myeloid blasts in the bone marrow
and spleen, consistent with transformation into AML. Similarly,
Cheng et al. (2013) showed that mice transplanted with bone
marrow cells overexpressing miR-29b developed splenomegaly
and an increase in myeloid bias index, which are accompanied
by reductions in 5hmC levels. Interestingly, the authors found
that expression of TET2 partially rescued this malignant pheno-
type. It remains unclear whether overexpression of TET1, TET2,
and TET3 together could completely rescue the phenotype. All
of the TET family members regulate DNA methylation and are
bona ﬁde targets of miR-29b, making this a possibility. Nev-
ertheless, these studies indicate that the enforced expression of
miR-29a in immature hematopoietic cells drives leukemic trans-
formation, and that this phenotype can be attributed, at least in
part, to the targeting of TET2. Moreover, the Han et al. (2010)
study emphasizes the need to investigate the function of poten-
tial leukemia-modifying genes in a cell-speciﬁc manner since the
functional consequences can vary dramatically based on cell con-
text. This point is well-illustrated by the ﬁnding that miR-29a
is up-regulated in patient LSC-enriched fractions and not in
non-LSC fractions, which in contrast to other studies that have
shown reducedmiR-29a levels inwhole PBMNC’s andBMCD34+
leukemic blasts (Wang et al., 2012b; Gong et al., 2014). Thus, the
down-regulation of miR-29’s observed in previous studies may be
due to the inclusion and dominance of non-LSC’s in the evaluated
cells.
Consistent with miR-29’s role in promoting leukemogenesis,
it appears that inhibiting miR-29 in established blasts may be a
promising therapeutic strategy. Injection of precursor miR-29b
oligonucleotides in mice engrafted with K562 tumors signiﬁ-
cantly reduce their size (Garzon et al., 2009a). Subsequent studies
showed that a transferrin-conjugated nanoparticle delivery system
for synthetic miR-29b (Tf-NP-miR-29b) suppressed AML growth,
impaired colony formation, and reduced cell viability in AML
patient samples. Tf-NP-miR-29b also reduced spleen weight and
increased overall survival in NSG mice transplanted with AML
cell lines (Huang et al., 2013). Similarly, intravenous injections
of NOD/SCID mice engrafted with AML with viral particles
expressingmiR-29a, -29b, and -29c reduced the number of CD33+
leukemic cells in the bone marrow and spleen by inhibiting pro-
liferation and stimulating apoptosis (Gong et al., 2014). While
the mechanism of leukemic blast clearance was not examined in
these studies, others have suggested that the therapeutic effect of
miR-29bmaybemediated through its regulationof c-Kit through a
feedback-loop (Liu et al., 2010). This is not surprising considering
that increased c-Kit activation, either through stimulation by its
ligand or secondary gain-of-function mutations, has been shown
to drive leukemogenesis. In this study, c-Kit was shown to acti-
vate the transcription factor, MYC, which subsequently binds to,
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and inhibits, the miR-29b promoter (Liu et al., 2010). The reduc-
tion in miR-29b expression was shown to positively regulate Sp1
levels, thus allowing the formation of the Sp1/NF-kB complex,
which binds regulatory sequences to increase c-Kit expression. It
was also shown to positively regulate the formation of a com-
plex with HDAC1, which further suppresses miR-29b expression.
In support of this model, pharmacologic inhibition of c-Kit with
bortezomib in NOD/SCID mice transplanted with c-Kit mutant
AML cells (FDC-P1/KITmut ) abrogated c-Kit mRNA levels and
increased miR-29b expression. In addition, FDC-P1/KITmut cells
exhibited reduced tumor size, tumor weight, and engraftment efﬁ-
ciency upon transfection with synthetic miR-29b. These ﬁndings
demonstrate the therapeutic potential of miR-29 oligonucleotides
and suggest that the down-regulation of miR-29b is particu-
larly critical to leukemogenesis in c-Kit-driven AML (Liu et al.,
2010).
CONCLUSION AND FUTURE DIRECTIONS
Although numerous miRNAs are dysregulated in AML, only
a few have been shown to play functional roles in myeloid
leukemogenesis (Table 2). Collectively, the data indicate that
these miRNAs induce hematopoietic malignancies by exerting
their biologic effects in developmental stage-speciﬁc manners.
A summary of the predicted stage at which each of these miR-
NAs exerts its leukemogenic function is indicated in Figure 4.
It is also worth mentioning that miRNAs may act in non-
hematopoietic cell-intrinsic manners to promote leukemogenesis,
as demonstrated by Raaijmakers et al. (2010), who showed that
deleting the miRNA processing enzyme, DICER1, in mouse
osteoprogenitors induces MDS which progresses to AML. These
studies suggest that the absence of one or more miRNAs in
bone marrow stromal cells may increase the predisposition
towards developing myeloid malignancies (Raaijmakers et al.,
2010).
miRNAs with leukemogenic roles have been identiﬁed pre-
dominantly through high-throughput gene expression analyses.
Despite the high number of miRNAs exhibiting altered expression
in AML, sequencing of patient samples has revealed that somatic
mutations in miRNAs are relatively rare events in human AML
(Cancer Genome Atlas Research Network, 2013). Thus, miRNA
deregulation in AML patients is largely due to alterations in
transcriptional and/or post-transcriptional regulation. Further-
more, miRNAs are normally processed post-transcriptionally in a
multi-step process involving DROSHA and DICER, each of which
is regulated by several signaling molecules and RNA-binding
proteins (Obernosterer et al., 2006; Thomson et al., 2006; Winter
et al., 2009; Saj and Lai, 2011). Thus, understanding the complex
regulation of the miRNAs that have been implicated in AML may
provide novel avenues for therapeutic development. Moreover,
many miRNAs are organized in clusters throughout the genome,
and are expressed in a concerted manner. Paradoxically, however,
individual members of a cluster can function in different or even
opposite manners. For example, while miR-125 can serve as an
oncogene in the context of breast cancer (Iorio et al., 2005; Scott
et al., 2007), its cluster partner, let-7, functions as a tumor sup-
pressor in the same context (Lee and Dutta, 2007). These results
suggest that miRNAs residing in clusters undergo different modes
of post-transcriptional regulation. Thus, differing modes of post-
transcriptional regulation of miRNAs within the same cluster
might explain how such miRNAs serve opposing roles.
Although few miRNAs are mutated in human AML, many are
known to be located in the proximity of breakpoints in chromo-
somal translocations/deletions (Calin et al., 2004). These observa-
tions suggest thatmiRNAsmay contribute to disease pathogenesis,
while the presence of additional genes in the deleted/translocated
regions implies a potential cooperativity with miRNAs in leuke-
mogenesis. In line with this idea, it is known that AML is a
multi-stepprocess, the understandingof which requires functional
analyses of co-occurring disease alleles (Jan et al., 2012; Chen et al.,
2014). This raises the possibility that genetic interaction stud-
ies between miRNAs and concurrently dysregulated or mutated
genes might provide more accurate models to study disease. For
instance, miR-146a is located in the del(5q) region observed in
some MDS patients along with about 40 other genes, including
the ribosomal protein RPS14 (Ebert et al., 2008). While miR-146a
studies have provided precious insight into our understanding of
MDS biology, they only partially recapitulate features of MDS.
Thus, experiments employing approaches that evaluate loss-of-
function del(5q) genes in combination with miR-146a loss might
provide a more nuanced understanding of MDS pathogenesis.
Identiﬁcation of target genes through which the pathogenic
miRNAs in AML exert their effects is critical to understanding dis-
ease biology. A limited number of targets have been validated for
each of these miRNAs and thus identiﬁcation of bona ﬁde target
genes remains a major challenge in the ﬁeld. Whereas some miR-
NAsmediate their function through a limited number of key target
genes, others exert their action through many. To identify target
genes mediating the effect of individual miRNAs, advanced tar-
get identiﬁcation methods such as whole proteomics approaches
and biochemical analyses of miRNA:mRNA interactions will be
required. These techniques includeRISC complex pull-down,RIP-
Seq, HITS-CLIP and PAR-CLIP, which have been summarized in
other reviews (Carroll et al., 2014). Furthermore, selective gener-
ation of knockin mouse models with mutations in the miRNA
binding sites in the 3′-UTR of potential target genes (Jan et al.,
2012) would assist the identiﬁcation of relevant miRNA targets.
Finding such target genes may provide additional promising ther-
apeutic targets that have not yet been described (Garzon et al.,
2010).
There are documented examples of the successful delivery of
miRNA oligonucleotides to target tissues in vivo including the
lung (Trang et al., 2011) and liver (Kota et al., 2009). Given the
critical role of miRNAs in leukemogenesis, investigators have eval-
uated whether they might be effective therapeutic targets in AML.
The potential use of miRNAs as therapeutic agents or targets in
AML is underscored by their ability to regulate multiple signaling
pathways that contribute to leukemogenesis (Li et al., 2007; Croce,
2008).
Two strategies may be employed to modulate miRNA activ-
ity: (i) enhancing the function of tumor supressor miRNAs using
miRNAmimics, and (ii) inhibiting the function of oncogenicmiR-
NAs by limiting their ability to bind to gene targets using antisense
oligos or miRNA sponges (Garzon et al., 2010). For such therapies
to ﬁnd their way into the clinic, efﬁcient and safe delivery of
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Table 2 | Summary of miRNAs with validated functional relevance in the pathogenesis of myeloid malignancies.
miRNA Location Expression In vitro phenotype In vivo phenotype Bona fide
targetsHuman Mouse
miR-125 Chr 19,
21, 11
Chr 17,
16, 9
• Highly expressed in HSCs
• Reduced with differentiation
• Increases HSC self-
renewal, decreases apoptosis,
confers aberrant self-renewal
in FL megakaryocyte erythroid
progenitors (MEPs) and
megakaryocytic progenitors
(MPs)
• Enhances long-term reconstitution,
reduces apoptosis in HSCs and progenitors,
increases myeloid output at the expense of
B cells. can lead to ALL at high doses as well
as MPN/AML at very high doses
Klf13, Bmf,
Bak1, Dicer,
ST18, ABTB1,
CBFB
miR-142 Chr 17 Chr 11 • Most highly expressed in
lymphoid and myeloid
progenitors
• Downregulated in AML
patient samples
• Ectopic expression in
MLL-AF4+ cell lines
suppressed cell proliferation,
induced apoptosis, and
downregulated multiple genes
known to regulate
self-renewal
• Ectopic expression in in
acute myeloid leukemia (AML)
cell lines increases PMA– and
ATRA-induced differentiation
Not investigated Cyclin T2,
TAB2
miR-146 Chr 5 Chr 11 • Expressed at relatively low
levels in stem and progenitors
and upregulated upon
differentiation
• Highly expressed in
macrophages and T cells
• Low expression in
megakaryocytic progenitors
(MPs)
• Overexpression leads to
decreased megakaryopoiesis
in human CD34+ HSPCs
• miR-146-null mice display hypersensitivity
to LPS challenge, increased
megakaryopoiesis. They also display
pancytopenia and GM expansion with aging
• miR-146 KD in murine HSPCs followed by
transplantation results in increased
megakaryopoiesis, and an MDS phenotype
with thrombocytosis and neutropenia
TRAF6, IRAK1
miR-155 Chr 21 Chr 16 • Relatively higher basal
expression in HSPCs
compared to more mature
populations, such as erythroid
progenitors
• Induced in innate immune
cells upon inﬂammatory
stimuli as well as activated B
andT cells
• Ectopic expression of
miR-155 in K562 cells leads to
a decreased CD41+
megakaryocytic differentiation
• Enforced expression in HSCs leads to
development of a MPN/MPD with abnormal
GM morphology, along with a reduction in
erythroid progenitors in the bone marrow
SHIP1, Cebpβ
miR-29 Chr 7, 1 Chr 6, 1 • Highest levels of expression
in HSCs and MPPs, followed
by LSCs, CMPs, MEPs, and
GMPs; levels decrease with
differentiation
• Increased in patient LSCs,
but not in non-LSCs
• Ectopic miR-29 expression
in AML cell lines leads to
global DNA hypomethylation
and reduces 5hmC levels;
• Positively regulates myeloid
differentiation, proliferation,
and apoptosis
• Ectopic expression reduces the size of
K562-laden tumors, via inhibiting proliferation
and stimulating apoptosis and increases OS
of mice with AML
• Ectopic expression in early hematopoietic
cells leads to induction of aberrant GMP
self-renewal and the development of MPD
with progression to AML
DNMT3A,
DNMT3B, Sp1,
TET family,
CDK6, CCNT2,
AKT2, HBP1
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FIGURE 4 | Summary of proposed developmental stages at which
microRNAs (miRNAs) functionally contribute in leukemogenesis.The
stages at which each of the ﬁve miRNAs described in this review exert their
effect in hematopoiesis and leukemogensis are depicted. miR-125 is a
positive regulator of HSC self-renewal, and depending on its level of
expression, can lead to biased myeloid or lymphoid differentiation. miR-146a
regulates HSC maintenance as well as megakaryocytic differentiation.
miR-155 is a positive regulator of GM differentiation and a negative regulator
of erythroid differentiation. miR-29 is a positive regulator of myeloid
differentiation, and overexpression can induce aberrant self-renewal of
GMP’s. HSC, hematopoietic stem cell; CMP, common myeloid progenitor;
MEP, megakaryocyte erythroid progenitor; RBC, red blood cell; GMP,
granulocyte macrophage progenitor; CLP, common lymphoid progenitor; ETP,
early thymic progenitor; NK, Natural Killer cell.
the targeting agents are required. Several groups have developed
different delivery systems for miRNA targeting treatments (van
Rooij and Kauppinen, 2014), including: (i) non-viral oligonu-
cleotides; (ii) viral constructs overexpressing the miRNA or its
antagomir (anti-sense oligo); and (iii) small-molecule delivery
systems, where miRNA oligonucleotides are conjugated to small-
molecules to ensure more efﬁcient delivery (Ibrahim et al., 2011;
Pramanik et al., 2011). Validating the optimal method of delivery
will represent a signiﬁcant challenge for miRNA-directed therapy
in the future.
Among the leukemogenic miRNAs discussed in this review,
miR-155 and miR-29 have been extensively studied as thera-
peutic targets in other contexts. Successful delivery of miR-155
oligonucleotides to the bone marrow has been conﬁrmed, with
the inhibition of miR-155 using a LNA (Takeshita et al., 2010)
antagomir that was shown to alleviate symptoms of graft-versus-
host disease (Ranganathan et al., 2012). In addition, systemically
administered LNA antagonists againstmiR-155 in amouse inﬂam-
mation model inhibited miR-155’s inﬂammatory effects in mouse
splenocytes (Worm et al., 2009). In the context of AML, miR-29b
oligonucleotide mimics appear to be promising therapies based on
their effects onAML patient samples in vitro (Garzon et al., 2009b)
and in K562-driven tumors in vivo (Garzon et al., 2009a). While
miR-29b directed treatments show promise, these studies have not
been performed using systemically delivered miRNA mimics. We
expect to see such studies in the future aimed at identifying and
validating more efﬁcient and speciﬁc in vivo delivery systems for
the treatment of AML.
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